Hamburg Highlights
TAGline • 1997David Ho proposes immunotherapeutic vaccination to help the immune system clear the long-lived “3rd” compartment of HIV-infected cells. These latently infected CD4+ T-cells with integrated HIV DNA currently represent the greatest obstacle to the potential eradication of HIV infection. And a British study may just beat him to the punch: Frances Gotch (London) reported that…
AIDS Activists Say New HIV Treatment Guidelines Could Revolutionize HIV Care for People With AIDS
Publication • 1997Maximal HIV Suppression becomes the Goal of Antiretroviral Therapy Unequal Access to Care Still Hinders Treatment Advances Members of the Treatment Action Group (TAG), a non-profit AIDS research and treatment advocacy group in New York City, offered strong praise for new guidelines on AIDS therapy announced today in the Federal Register. The new guidelines, developed…
Random Gleanings: Expanded Access for Nevirapine and Delavirdine; OAR Loses Out on 1996 Budgetary Authority; Lowering the Vaccine Goalpost
TAGline • 1996Expanded Access for Nevirapine and Delavirdine Makers of the non-nucleoside reverse transcriptase inhibitor delavirdine and nevirapine (Viramune) have filed for regulatory approval and announced temporary programs for early access to the drugs for HIV-infected individuals with CD4 cell counts < 200 (this may change). To inquire about the program for nevirapine, call Boehringer Ingelheim at…
White House Summit: Clinton, Shalala, Fleming Host Gathering of AIDS Advocates, Care Givers and People Living with HIV at Day-Long Conference
TAGline • 1996Clinton, Shalala, Fleming Host Gathering of AIDS Advocates, Care Givers and People Living with HIV at Day-Long Conference Election Year Sleight of Hand? On December 6, 1995, the White House held a one-day conference on HIV and AIDS. TAG Policy Director Gregg Gonsalves was one of the three hundred or so invited guests, and one…
Annus Mirabilis: A Look Back at an Extraordinary Year for Basic and Clinical Research on AIDS — and the Questions Raised
TAGline • 1996A Look Back at an Extraordinary Year for Basic and Clinical Research on AIDS — and the Questions Raised Additional Surprises Expected The year 1996 witnessed seismic developments in AIDS research. On many fronts — the basic and the clinical, the biomedical and the behavioral — the very ground has shifted under our feet. It…
Review and Reform: OAR Advisory Panel Would Meld 12 Trials Networks into One and Requests Improved Institute Collaboration
TAGline • 1996OAR Advisory Panel Would Meld 12 Trials Networks into One and Requests Improved Institute Collaboration 15 Studies of Oral Interferon The six Area Review Panels (ARPs) of the NIH AIDS Research Program Evaluation Working Group of the OAR Advisory Council (known informally, after the group’s chairman Dr. Arnold J. Levine, as the “Levine committee”) included…
The Six Area Review Panels (ARPs): Of the NIH AIDS Research Program Evaluation Working Group of the Office of AIDS Research (OAR) Advisory Council (the “Levine Committee”)
TAGline • 1996Of the NIH AIDS Research Program Evaluation Working Group of the Office of AIDS Research (OAR) Advisory Council (the “Levine Committee”) Natural History, Epidemiology, and Prevention Research Etiology and Pathogenesis Drug Discovery Vaccine Research and Development Clinical Trials Ad hoc sub-panels: Animal Models; Opportunistic Infections Research; Alternative and Complementary Therapy Research Behavioral, Social Science, and…
Diversity Threshold: New Model of Immune Defense to HIV Shows How Nature of Response Might Determine Eventual Outcome
TAGline • 1995New Model of Immune Defense to HIV Shows How Nature of Response Might Determine Eventual Outcome Sloppy RT, Bane of All A provocative research paper initially published in the international weekly science journal Nature (“Antigenic oscillations and shifting immunodominance in HIV-1 infections,” Nowak M.A. et al. Nature 375:606-11) has been reworked into a more readable…
Dendritic Cells in Drag: Inauspicious Debut for HIV Specific CTLs; New Concerns about IL-12; Neutralizing Approaches for “Bad” Cytokines; Parke-Davis Targets Cellular Factors
TAGline • 1995Inauspicious Debut for HIV Specific CTLs; New Concerns about IL-12; Neutralizing Approaches for “Bad” Cytokines; Parke-Davis Targets Cellular Factors Souped-Up Abs from LTNPs The Clinical Immunology Society’s 2nd HIV Immune-based Therapies Workshop was held in Baltimore on January 27-29. Attendance seemed a little down compared to last year’s meeting, which may simply reflect the increased…
Random Gleanings: FDA Just Says “No” To Salk Immunogen; Heralding the Naked Emperor, Part II; OAR’s Dr. Paul Speaks; Varmus Selects New Director for Office of Alternative Medicine
TAGline • 1995FDA Just Says “No” To Salk Immunogen. The illustrious Dr. Jonas Salk and officials of his Immune Response Corp. appeared before an FDA advisory committee on 26 January seeking approval for large-scale Phase III efficacy trials of its envelope depleted HIV (Zairean strain) as a possible therapeutic vaccine. (The design was originally intended to be…